Sector: Healthcare | Industry: Pharmaceuticals |
Company Contact | |
Address: | 5310 Beethoven St LOS ANGELES CA 90066 |
Tel: | 1-310-3063636 |
Website: | https://ir.irwinnaturals.com |
IR: | See website |
Key People | ||
Klee Irwin Chairman of the Board, Chief Executive Officer | Sean Sand Chief Financial Officer, Corporate Secretary | Michael Berg Executive Vice President - Sales and Marketing, Irwin Nevada |
Rebecca Pearman Executive Consultant, Irwin Nevada | Daniel Wing Chief Operating Officer, Irwin Nevada |
Business Overview |
Irwin Naturals Inc. (Irwin) is a nutraceutical company. The Company is engaged in distributing cannabidiol (CBD) products in mass-market and health food chain stores across the United States. Irwin's portfolio of herbal products is available in more than 100,000 retail doors across North America. The Company's full range of Vitamin, CBD, and Supplements features over 100 products, created to address mood and brain function, better sleep, sports performance, sexual health, immune support, weight management, women's health and men's health. The Company's ketamine clinic, Emergence, is an infusion clinic that offers intravenous (IV) ketamine for the treatment of depression, post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), anxiety, bipolar disorder, migraines, and multiple chronic pain conditions such as complex regional pain syndrome (CRPS), reflex sympathetic dystrophy (RSD) and fibromyalgia. |
Financial Overview |
For the nine months ended 30 September 2023, Irwin Naturals Inc revenues decreased 4% to $63.7M. Net loss totaled $14.7M vs. income of $668K. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net loss reflects Selling, General and Administrative Expe increase of 25% to $34.4M (expense), Interest Expense - Balancing value increase from $468K to $1.8M (expense). |
Employees: | 111 as of Dec 31, 2020 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $28.46M as of Sep 30, 2023 |
Annual revenue (TTM): | $118.57M as of Sep 30, 2023 |
EBITDA (TTM): | -$7.28M as of Sep 30, 2023 |
Net annual income (TTM): | -$26.44M as of Sep 30, 2023 |
Free cash flow (TTM): | -$2.02M as of Sep 30, 2023 |
Net Debt Last Fiscal Year: | $33.10M as of Sep 30, 2023 |
Shares outstanding: | 324,453,608 as of Nov 6, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |